Related Experiment Video

Updated: Jun 2, 2025

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

223

UBE2N: Hope on the Cancer Front, How to Inhibit This Promising Target Prospect?

Florian Schwalen1,2, Côme Ghadi1, Léonie Ibazizene3,4

  • 1Université de Caen Normandie, CERMN UR4258, Normandie Univ, F-14000 Caen, France.

Journal of Medicinal Chemistry
|January 14, 2025
PubMed

Insights

Researchers are exploring UBE2N inhibitors for cancer therapy. Noncovalent inhibitors show promise over covalent ones, but drug properties must be assessed early for clinical success.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Oncology

Background:

  • UBE2N protein is vital for DNA repair and a promising target for anticancer drug development.
  • Developing novel UBE2N inhibitors (UBE2Ni) is crucial for innovative cancer therapies.

Purpose of the Study:

  • To review and guide the design of new UBE2N inhibitors.
  • To analyze UBE2N protein structure and interaction sites using chemoinformatics.
  • To compare covalent and noncovalent UBE2Ni, highlighting advantages of noncovalent approaches.

Main Methods:

  • Chemoinformatic structural analysis of UBE2N protein.
  • Analysis of protein-interaction sites.
  • Review of existing UBE2N inhibitors and their development stages.

Main Results:

  • Noncovalent UBE2Ni present potential advantages over covalent inhibitors, particularly regarding selectivity.
  • Early assessment of compound druggability is essential for hit-to-lead progression.
  • Pharmacokinetic properties of UBE2Ni pose a significant challenge for therapeutic application.

Conclusions:

  • Noncovalent UBE2N inhibitors offer a promising avenue for cancer therapy development.
  • Addressing pharmacokinetic challenges early is critical for translating UBE2Ni into human therapies.
  • Further research into UBE2Ni design and druggability is warranted.

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.5K
A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants06:35

A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants

Published on: October 10, 2022

1.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
10.9K